Time Will Tell Whether Once-monthly Products Ultimately Dominate or Merely Provide Another Option in the BP Market

Daisuke Inoue, Associate Professor, Teikyo University’s Chiba Medical Center A year has gone by since the once-monthly bisphosphonate (BP) preparations Recalbon/Bonoteo (minodronic acid hydrate) were launched onto the market for osteoporosis treatments and the ban on their long-term prescription was...read more